WallStSmart

Frontdoor Inc (FTDR)vsMEDIFAST INC (MED)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Frontdoor Inc generates 443% more annual revenue ($2.09B vs $385.79M). FTDR leads profitability with a 12.2% profit margin vs -4.8%. MED appears more attractively valued with a PEG of 0.97. FTDR earns a higher WallStSmart Score of 50/100 (D+).

FTDR

Hold

50

out of 100

Grade: D+

Growth: 4.7Profit: 7.0Value: 7.3Quality: 5.5
Piotroski: 4/9Altman Z: 2.14

MED

Hold

45

out of 100

Grade: D

Growth: 2.0Profit: 2.0Value: 6.7Quality: 6.0
Piotroski: 2/9Altman Z: 5.46
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

FTDRSignificantly Overvalued (-139.9%)

Margin of Safety

-139.9%

Fair Value

$23.46

Current Price

$57.74

$34.28 premium

UndervaluedFair: $23.46Overvalued

Intrinsic value data unavailable for MED.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

FTDR2 strengths · Avg: 9.0/10
Return on EquityProfitability
106.0%10/10

Every $100 of equity generates 106 in profit

P/E RatioValuation
17.2x8/10

Attractively priced relative to earnings

MED3 strengths · Avg: 9.3/10
Price/BookValuation
0.5x10/10

Reasonable price relative to book value

Altman Z-ScoreHealth
5.4610/10

Safe zone — low bankruptcy risk

PEG RatioValuation
0.978/10

Growing faster than its price suggests

Areas to Watch

FTDR4 concerns · Avg: 3.3/10
PEG RatioValuation
2.384/10

Expensive relative to growth rate

Price/BookValuation
16.9x4/10

Trading at 16.9x book value

Operating MarginProfitability
3.0%3/10

Operating margin of 3.0%

EPS GrowthGrowth
-84.0%2/10

Earnings declined 84.0%

MED4 concerns · Avg: 2.5/10
Market CapQuality
$109.91M3/10

Smaller company, higher risk/reward

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

Return on EquityProfitability
-9.1%2/10

ROE of -9.1% — below average capital efficiency

Revenue GrowthGrowth
-36.9%2/10

Revenue declined 36.9%

Comparative Analysis Report

WallStSmart Research

Bull Case : FTDR

The strongest argument for FTDR centers on Return on Equity, P/E Ratio. Revenue growth of 13.4% demonstrates continued momentum.

Bull Case : MED

The strongest argument for MED centers on Price/Book, Altman Z-Score, PEG Ratio. PEG of 0.97 suggests the stock is reasonably priced for its growth.

Bear Case : FTDR

The primary concerns for FTDR are PEG Ratio, Price/Book, Operating Margin. Debt-to-equity of 3.80 is elevated, increasing financial risk.

Bear Case : MED

The primary concerns for MED are Market Cap, Piotroski F-Score, Return on Equity.

Key Dynamics to Monitor

FTDR profiles as a value stock while MED is a turnaround play — different risk/reward profiles.

FTDR carries more volatility with a beta of 1.32 — expect wider price swings.

FTDR is growing revenue faster at 13.4% — sustainability is the question.

FTDR generates stronger free cash flow (95M), providing more financial flexibility.

Bottom Line

FTDR scores higher overall (50/100 vs 45/100) and 13.4% revenue growth. Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Frontdoor Inc

CONSUMER CYCLICAL · PERSONAL SERVICES · USA

front door, inc. The company is headquartered in Memphis, Tennessee.

Visit Website →

MEDIFAST INC

CONSUMER CYCLICAL · PERSONAL SERVICES · USA

Medifast, Inc. manufactures and distributes weight loss, weight management, healthy living products, and other consumable health and nutrition products in the United States and Asia-Pacific. The company is headquartered in Baltimore, Maryland.

Visit Website →

Want to dig deeper into these stocks?